|
US7553929B2
(en)
*
|
1994-06-13 |
2009-06-30 |
Vanderbilt University |
Cell permeable peptides for inhibition of inflammatory reactions and methods of use
|
|
US6495518B1
(en)
*
|
1994-06-13 |
2002-12-17 |
Vanderbilt University |
Method for importing biologically active molecules into cells
|
|
FR2739621B1
(fr)
*
|
1995-10-05 |
1997-12-05 |
Centre Nat Rech Scient |
Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
|
|
US5962415A
(en)
*
|
1996-09-20 |
1999-10-05 |
Bristol-Myers Squibb Co. |
Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
|
|
GB2337329B
(en)
*
|
1997-04-30 |
2001-09-05 |
Imp Cancer Res Tech |
Inhibitors of nuclear protein/nuclear receptor interaction
|
|
GB9708676D0
(en)
*
|
1997-04-30 |
1997-06-18 |
Imp Cancer Res Tech |
Chemical compounds
|
|
IL142869A0
(en)
*
|
1998-11-13 |
2002-03-10 |
Cyclacel Ltd |
Transport vectors
|
|
DK2385124T3
(da)
*
|
1999-05-14 |
2013-11-18 |
Arbor Vita Corp |
Peptider, eller peptid-analoger, til modulering af bindingen af et PDZ protein og et PL protein
|
|
DE60037970T2
(de)
|
1999-06-28 |
2008-08-21 |
Inter-K Pty. Ltd., Newcastle |
Verfahren zur modulierung von integrin-vermittelter zellaktivitaet und hierfuer geeignete reagenzien
|
|
DE19933492B4
(de)
*
|
1999-07-16 |
2008-01-10 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
|
|
US6312956B1
(en)
|
1999-10-01 |
2001-11-06 |
Vanderbilt University |
Nuclear targeted peptide nucleic acid oligomer
|
|
US8183339B1
(en)
|
1999-10-12 |
2012-05-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US20040082509A1
(en)
|
1999-10-12 |
2004-04-29 |
Christophe Bonny |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US6844324B1
(en)
*
|
1999-11-12 |
2005-01-18 |
Massachusetts Institute Of Technology |
Modular peptide mediated intracellular delivery system and uses therefore
|
|
CA2392490A1
(en)
*
|
1999-11-24 |
2001-05-31 |
Mcs Micro Carrier Systems Gmbh |
Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
|
|
EP1862471A3
(en)
*
|
2000-02-07 |
2008-05-28 |
Wisconsin Alumni Research Foundation |
Pharmacologically active antiviral peptides and methods of their use
|
|
WO2001057072A2
(en)
*
|
2000-02-07 |
2001-08-09 |
Wisconsin Alumni Research Foundation |
Pharmacologically active antiviral peptides and methods of their use
|
|
GB0103110D0
(en)
|
2000-08-25 |
2001-03-28 |
Aventis Pharma Inc |
A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
|
|
CA2444696A1
(en)
*
|
2001-04-19 |
2002-10-31 |
Bristol-Myers Squibb Company |
Polynucleotides and polypeptides associated with the nf-kb pathway
|
|
US20040086896A1
(en)
*
|
2001-04-19 |
2004-05-06 |
Julie Carman |
Polynucleotides and polypeptides associated with the NF-kB pathway
|
|
DE60335101D1
(de)
*
|
2002-04-25 |
2011-01-05 |
Toagosei Co Ltd |
Antimikrobielles polypeptid und nutzung davon
|
|
WO2005037308A1
(en)
*
|
2003-10-17 |
2005-04-28 |
Inter-K Pty Limited |
Methods and agents for the treatment of cancer
|
|
JP4524671B2
(ja)
*
|
2003-10-29 |
2010-08-18 |
東亞合成株式会社 |
抗菌ペプチド及びその利用
|
|
WO2005060541A2
(en)
*
|
2003-12-01 |
2005-07-07 |
Wisconsin Alumni Research Foundation |
Peptides and methods for inducing cellular resistance to infection
|
|
US20050203150A1
(en)
*
|
2004-03-09 |
2005-09-15 |
Haffar Omar K. |
Compounds, compositions and methods for inhibiting or treating HIV-1
|
|
JP4507080B2
(ja)
*
|
2004-07-30 |
2010-07-21 |
東亞合成株式会社 |
抗菌ペプチド及びその利用
|
|
WO2006056227A1
(en)
*
|
2004-11-27 |
2006-06-01 |
Eberhard-Karls- Universität Tübingen Universitätsklinikum |
Conjugates comprising the active agent and flanking or branched-chain peptides
|
|
JP4730584B2
(ja)
*
|
2004-12-06 |
2011-07-20 |
東亞合成株式会社 |
抗菌ペプチド及びその利用
|
|
WO2006088010A1
(ja)
*
|
2005-02-15 |
2006-08-24 |
Toagosei Co., Ltd. |
抗菌ペプチド及びその利用
|
|
US8080517B2
(en)
|
2005-09-12 |
2011-12-20 |
Xigen Sa |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
WO2007031098A1
(en)
|
2005-09-12 |
2007-03-22 |
Xigen S.A. |
Cell-permeable peptide inhibitors of the jnk signal transduction pathway
|
|
JP2011512364A
(ja)
*
|
2008-02-22 |
2011-04-21 |
インター−ケイ ピーティーワイ リミテッド |
治療用ペプチド
|
|
WO2009143865A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
WO2009143864A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
|
|
EP2454276A4
(en)
|
2008-07-17 |
2013-07-10 |
Inter K Pty Ltd |
THERAPEUTIC AGENTS
|
|
WO2010072228A1
(en)
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
|
WO2011160653A1
(en)
|
2010-06-21 |
2011-12-29 |
Xigen S.A. |
Novel jnk inhibitor molecules
|
|
AU2010362444B2
(en)
|
2010-10-14 |
2015-08-06 |
Xigen Inflammation Ltd. |
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
|
|
WO2013091670A1
(en)
|
2011-12-21 |
2013-06-27 |
Xigen S.A. |
Novel jnk inhibitor molecules for treatment of various diseases
|
|
WO2015197097A1
(en)
|
2014-06-26 |
2015-12-30 |
Xigen Inflammation Ltd. |
New use for jnk inhibitor molecules for treatment of various diseases
|
|
ES2870085T3
(es)
|
2013-06-26 |
2021-10-26 |
Xigen Inflammation Ltd |
Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
|
|
WO2014206427A1
(en)
|
2013-06-26 |
2014-12-31 |
Xigen Inflammation Ltd. |
New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
|
RU2721423C2
(ru)
|
2013-08-07 |
2020-05-19 |
Йеда Ресеарч Энд Девелопмент Ко. Лтд. |
Пептиды, способные реактивировать мутанты р53
|
|
KR20150050646A
(ko)
*
|
2013-10-29 |
2015-05-11 |
삼성전자주식회사 |
융합 펩타이드 및 이의 세포막투과를 위한 용도
|
|
AU2017214733B2
(en)
*
|
2016-02-04 |
2022-09-29 |
Yeda Research And Development Co. Ltd. |
Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
|
|
JP7450983B2
(ja)
*
|
2020-02-18 |
2024-03-18 |
セリベリー セラピューティクス，インコーポレーテッド |
サイトカインストーム又は炎症性疾患を抑制するために改善された細胞透過性核輸送阻害剤合成ペプチド及びその用途
|